Kidney pelvis sarcomatoid transitional cell carcinoma
diseaseOn this page
Also known as infiltrating renal pelvis urothelial carcinoma, sarcomatoid variantrenal pelvis sarcomatoid transitional cell carcinomasarcomatoid transitional cell carcinoma of kidney pelvissarcomatoid transitional cell carcinoma of renal pelvissarcomatoid transitional cell carcinoma of the kidney pelvissarcomatoid transitional cell carcinoma of the renal pelvis
Summary
Kidney pelvis sarcomatoid transitional cell carcinoma (MONDO:0004009) is a cancer and 1 clinical trial. Top therapeutic interventions include tremelimumab. A subtype of sarcomatoid transitional cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | kidney pelvis sarcomatoid transitional cell carcinoma |
| Mondo ID | MONDO:0004009 |
| DOID | DOID:6844 |
| NCIT | C6186 |
| UMLS | C1335752 |
| MedGen | 233403 |
| GARD | 0023773 |
| Anatomy (UBERON) | UBERON:0001224 |
| Is cancer (heuristic) | yes |
Also known as: infiltrating renal pelvis urothelial carcinoma, sarcomatoid variant · kidney pelvis sarcomatoid transitional cell carcinoma · renal pelvis sarcomatoid transitional cell carcinoma · sarcomatoid transitional cell carcinoma of kidney pelvis · sarcomatoid transitional cell carcinoma of renal pelvis · sarcomatoid transitional cell carcinoma of the kidney pelvis · sarcomatoid transitional cell carcinoma of the renal pelvis
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › sarcomatoid carcinoma › sarcomatoid transitional cell carcinoma › kidney pelvis sarcomatoid transitional cell carcinoma
Related subtypes (2): infiltrating bladder urothelial carcinoma sarcomatoid variant, bladder sarcomatoid transitional cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02812420 | EARLY_PHASE1 | ACTIVE_NOT_RECRUITING | Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TREMELIMUMAB | 4 | 1 |
Related Atlas pages
- Drugs: Tremelimumab